DR. LAURENCE M. CORASH, M.D.
Osteopathic Medicine at Parnassus Ave, San Francisco, CA
License number
California G47181
Category
Osteopathic Medicine
Type
Internal Medicine
License number
California G47181
Category
Osteopathic Medicine
Type
Hematology
Address
Address
505 Parnassus Ave, San Francisco, CA 94143
Phone
(415) 353-1672
(415) 353-1804 (Fax)
(415) 476-4029
(415) 476-4150 (Fax)
(415) 353-1804 (Fax)
(415) 476-4029
(415) 476-4150 (Fax)
Personal information
See more information about LAURENCE M. CORASH at radaris.comName
Address
Phone
1070 Green St APT 1900, San Francisco, CA 94133
1000 Chestnut St, San Francisco, CA 94109
1070 Green St, San Francisco, CA 94133
San Francisco, CA
Professional information
Chief Medical Officer At Cerus
Position:
Chief Medical Officier at Cerus Europe BV, Chief Medical Officer at Cerus
Location:
San Francisco Bay Area
Industry:
Biotechnology
Work:
Cerus Europe BV
since 1997
-
Chief Medical Officier
Cerus
since Jan 1992
-
Chief Medical Officer
University of California Medical Center, San Francisco
Jan 1982 - Jan 1997
-
Chef, Clinical Laboratory Hematology Service
Education:
New York University School of Medicine 1965 - 1969
MD, Medicine Dartmouth College 1961 - 1965
AB, History
MD, Medicine Dartmouth College 1961 - 1965
AB, History
Laurence M Corash, San Francisco CA
Specialties:
Hematologist
Address:
505 Parnassus Ave, San Francisco, CA 94143
Education:
New York University, School of Medicine - Doctor of Medicine
National Institutes of Health-Clinical Center - Residency - Hematology
Bellevue Hospital Center - Residency - Internal Medicine
National Institutes of Health-Clinical Center - Residency - Hematology
Bellevue Hospital Center - Residency - Internal Medicine
Board certifications:
American Board of Internal Medicine Certification in Internal Medicine, American Board of Internal Medicine Sub-certificate in Hematology (Internal Medicine), American Board of Pathology Sub-certificate in Hematology (Pathology)
Dr. Laurence M Corash, San Francisco CA - MD (Doctor of Medicine)
Specialties:
Hematology, Hematopathology
Address:
505 Parnassus Ave, San Francisco 94143
(415) 353-1672 (Phone), (415) 353-1804 (Fax)
UNIVERSITY OF CALIFORNIA SAN FRANCISCO MEDICAL CENTER
185 Berry St SUITE 2000, San Francisco 94107
(415) 353-1723 (Phone), (415) 353-4767 (Fax)
CORASH, LAURENCE MD
1070 Green St SUITE 1900, San Francisco 94133
(925) 288-6118 (Phone), (925) 603-1724 (Fax)
(415) 353-1672 (Phone), (415) 353-1804 (Fax)
UNIVERSITY OF CALIFORNIA SAN FRANCISCO MEDICAL CENTER
185 Berry St SUITE 2000, San Francisco 94107
(415) 353-1723 (Phone), (415) 353-4767 (Fax)
CORASH, LAURENCE MD
1070 Green St SUITE 1900, San Francisco 94133
(925) 288-6118 (Phone), (925) 603-1724 (Fax)
Certifications:
Hematology, 1976, Hematology & Pathology, 1977, Internal Medicine, 1973
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
505 Parnassus Ave, San Francisco 94143
CORASH, LAURENCE MD
1070 Green St SUITE 1900, San Francisco 94133
UNIVERSITY OF CALIFORNIA SAN FRANCISCO MEDICAL CENTER
185 Berry St SUITE 2000, San Francisco 94107
UCSF Medical Center
505 Parnassus Ave, San Francisco 94143
CORASH, LAURENCE MD
1070 Green St SUITE 1900, San Francisco 94133
UNIVERSITY OF CALIFORNIA SAN FRANCISCO MEDICAL CENTER
185 Berry St SUITE 2000, San Francisco 94107
UCSF Medical Center
505 Parnassus Ave, San Francisco 94143
Education:
Medical School
New York University
Graduated: 1969
Bellevue Hospital Center
Natl Inst Hlth
New York University
Graduated: 1969
Bellevue Hospital Center
Natl Inst Hlth
Synthetic Media For Blood Components
US Patent:
6566046, May 20, 2003
Filed:
Dec 7, 2000
Appl. No.:
09/732174
Inventors:
Lily Lin - Berkeley CA
Laurence Corash - San Francisco CA
Marc Payrat - Nivelles, BE
Laurence Corash - San Francisco CA
Marc Payrat - Nivelles, BE
Assignee:
Baxter International Inc. - Deerfield IL
Cerus Corporation - Concord CA
Cerus Corporation - Concord CA
International Classification:
A01N 102
US Classification:
435 2, 604 4, 604 20
Abstract:
Synthetic media formulations are disclosed for use with blood preparations intended for in vivo use, including synthetic media formulations to be employed in conjunction with the photodecontamination of platelets.
Proralen Inactivation Of Microorganisms And Psoralen Removal
US Patent:
5709991, Jan 20, 1998
Filed:
Jun 7, 1995
Appl. No.:
8/480013
Inventors:
Lily Lin - Berkeley CA
Laurence Corash - San Francisco CA
John Tessman - San Leandro CA
George D. Cimino - Lafayette CA
Stephen T. Isaacs - Orinda CA
Laurence Corash - San Francisco CA
John Tessman - San Leandro CA
George D. Cimino - Lafayette CA
Stephen T. Isaacs - Orinda CA
Assignee:
Cerus Corporation - Concord CA
International Classification:
A01N 102, A61M 3500
US Classification:
435 2
Abstract:
Methods are disclosed for photodecontamination to inactivate microorganisms in platelet preparations and for removal of psoralen after photodecontamination. Removal is achieved by contacting the psoralen with a psoralen-binding polymer.
Synthetic Media Compositions For Inactivating Bacteria And Viruses In Blood Preparations With 8-Methoxypsoralen
US Patent:
5459030, Oct 17, 1995
Filed:
Jun 2, 1993
Appl. No.:
8/072485
Inventors:
Lily Lin - Berkeley CA
Laurence Corash - San Francisco CA
Laurence Corash - San Francisco CA
Assignee:
Steritech, Inc. - Concord CA
International Classification:
A01N 102, A61K 4100, A61M 3700
US Classification:
435 2
Abstract:
Synthetic media formulations are disclosed for use with blood preparations intended for in vivo use, including synthetic media formulations to be employed in conjunction with the photodecontamination of platelets using 8-methoxypsoralen.
Method Of Blood Component Decontamination By Glucose Addition
US Patent:
5176921, Jan 5, 1993
Filed:
May 11, 1989
Appl. No.:
7/350335
Inventors:
Gary P. Wiesehahn - Alameda CA
Laurence Corash - San Francisco CA
Laurence Corash - San Francisco CA
Assignee:
Diamond Scientific Co. - Des Moines IA
University of California - Oakland CA
University of California - Oakland CA
International Classification:
A61K 3514
US Classification:
424529
Abstract:
Biological compositions are freed of functional polynucletides by treatment of the biological composition with psoralen derivatives under irradiation conditions in which the proteins retain their original physiological activities and any polynucleotide present is rendered inactive. More specifically blood components are decontaminated of viruses by the addition of psoralen and irradiation and thereafter adding glucose.
Intravenous Administration Of Psoralen
US Patent:
5618662, Apr 8, 1997
Filed:
Jan 21, 1994
Appl. No.:
8/184016
Inventors:
Lily Lin - Berkeley CA
Laurence Corash - San Francisco CA
Laurence Corash - San Francisco CA
Assignee:
Cerus Corporation - Concord CA
International Classification:
A01N 102, C12N 1300, A61K 3514
US Classification:
435 2
Abstract:
Intravenous administration of 8-methoxypsoralen is disclosed, and more specifically intravenous administration of 8-methoxypsoralen-blood preparations, including platelets. Random donor platelet bags are treated, stored and pooled prior to transfusion.
Synthetic Media For Blood Components
US Patent:
5908742, Jun 1, 1999
Filed:
Aug 5, 1996
Appl. No.:
8/692444
Inventors:
Lily Lin - Berkeley CA
Laurence Corash - San Francisco CA
Jean Marc Payrat - Nivelles, BE
Laurence Corash - San Francisco CA
Jean Marc Payrat - Nivelles, BE
Assignee:
Cerus Corporation - Concord CA
International Classification:
A01N 102
US Classification:
435 2
Abstract:
Synthetic media formulations are disclosed for use with blood preparations intended for in vivo use, including essentially magnesium free synthetic media formulations to be employed in conjunction with the photodecontamination of platelets.
Synthetic Media For Blood Components
US Patent:
6251580, Jun 26, 2001
Filed:
Jan 29, 1999
Appl. No.:
9/240067
Inventors:
Lily Lin - Berkeley CA
Laurence Corash - San Francisco CA
Jean Marc Payrat - 1400 Nivelles, BE
Laurence Corash - San Francisco CA
Jean Marc Payrat - 1400 Nivelles, BE
International Classification:
A01N 102
US Classification:
435 2
Abstract:
Synthetic media formulations are disclosed for use with blood preparations intended for in vivo use, including synthetic media formulations to be employed in conjunction with the photodecontamination of platelets.